CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
- May 19th, 2023
- 830 views
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachusetts has been granted, relocating the case to the Eastern District of Virginia. This transfer is expected to expedite the progress of the litigation significantly and potentially lead to a trial date as early as 2024.
In pre-market trading, $CVAC is currently valued at $8.92, showing an increase of $0.16 (+1.83%).
Ambrx Biopharma Inc. (Nasdaq: AMAM) has been initiated with an Overweight rating and a price target of $25 by Cantor Fitzgerald.
$AMAM is currently trading at $13.80 in pre-market, experiencing a slight increase of $0.03 (+0.22%).
Additionally, Legend Biotech Corporation (Nasdaq: LEGN) has received a price target raise from Barclays, with the target being increased from $65 to $90.
In pre-market trading, $LEGN is currently trading at $70.09, reflecting an increase of $1.15 (+1.67%).
Please note that the stock prices and pre-market movements mentioned here are for illustrative purposes and may not reflect the current market conditions at the time of reading.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
November 18th, 2026November 18th, 2026Treasury, IRS Issue Final Rules to Help Hardworking Americans Build a Financially Secure Retirement
November 17th, 2026November 17th, 2026What Wall Street Expects From NVIDIA, Disney, and Elbit Systems
November 15th, 2026




Member Login